Dublin, May 08, 2018 -- The "Exosomes & Liquid Biopsies Europe 2018" conference has been added to ResearchAndMarkets.com's offering.
The Exosomes and Liquid Biopsies Europe 2018 Conference brings together academic researchers, industry researchers, as well as biotechnology and pharmaceutical companies to explore the expanding and evolving field whereby circulating biomarkers of various classes are being evaluated for their potential to be developed into minimally-invasive diagnostics and liquid biopsies for cancer as well as other disease classes.
This Exosomes and Liquid Biopsies 2018 Conference focuses primarily on biofluid-based molecular biomarkers, such as circulating tumor DNA (ctDNA) as well as circulating tumor cells (CTCs), protein-based circulating biomarkers, and exosomes/extracellular vesicles (EVs). There is much interest in the potential of ctDNA and EVs for developing biological fluid-based biopsies (such as using plasma, urine, or other biofluids) and the presenters in this conference bring together the most up-to-date information and current state-of-the-field.
The conference further explores the potential of various minimally-invasive circulating biomarker classes, such as circulating-free DNA (cfDNA), CTCs, and Extracellular Vesicles (EVs), for development of novel diagnostics for early patient monitoring.
Another component of this conference is the exploration of the science behind Exosomes and Extracellular Vesicles - Diagnostic and Therapeutic Potential.
The conference is being held in Rotterdam, The Netherlands-an excellent venue for networking with connections across The Netherlands, Europe and Worldwide. The conference includes an exhibition bringing together companies from around the world focused on developing technologies, tools, products and services serving the liquid biopsy field.
The Conference Chairman and Chief Scientific Advisor is Professor Dominique de Kleijn, Professor, University Medical Center Utrecht, The Netherlands.
Agenda:
- Circulating Tumor Cells (CTCs): Potential for Development of Liquid Biopsies
- Circulating Tumor DNA (ctDNA): Potential for Development of Liquid Biopsies
- Emerging Technologies and Emerging Companies Showcase
- Exosomes and Extracellular Vesicles (EVs): Potential for Development of Liquid Biopsies
- Exosomes as Delivery Vehicles and Therapeutic Applications of Exosomes
- Extracellular Nucleic Acids in the Circulation: Circulating Free DNA, Extracellular RNAs and Circulating microRNAs/Long Non-Coding RNAs
- Extracellular Vesicles (EV) in Cancer, Cardiovascular Disease, Neurological Diseases and Beyond
- Grants and Awards across the EU for Exosomes and Liquid Biopsy Research
- Regulatory Landscape for Liquid Biopsies (EU, US and Asia/Pacific)
For more information about this conference visit https://www.researchandmarkets.com/research/bscdcc/exosomes_and?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: In Vitro Diagnostics


Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests
SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints
Same sparkle, different story: how lab-grown diamonds are transforming the market
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 



